Your session is about to expire
← Back to Search
Futibatinib for Cancer
Study Summary
This trial will study the effects of futibatinib on patients with various cancers caused by aberrant FGFR genes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 407 Patients • NCT02052778Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain metastases are either untreated or not stable for over a month.I have had at least 2 treatments for my advanced cancer.I cannot have a stem cell transplant or it didn't work for me, and no other treatments are suitable.My stomach or GEJ cancer worsened after the last treatment.My cancer has returned or worsened after standard treatment.My cancer is a type of blood cancer with a specific genetic change.My cancer has a specific FGFR gene change.I am fully active or restricted in physically strenuous activity but can do light work.You have a medical condition related to the balance of calcium and phosphorus in your body that the doctor considers important.My cancer is advanced or has spread, and tests show FGFR1-4 changes.My cancer in the stomach or gastroesophageal junction is advanced and has a specific genetic feature (FGFR2 amplification).I have been treated with an FGFR inhibitor before.I have abnormal mineral deposits in organs like the heart or lungs, considered significant by my doctor.I have a history of certain health disorders.
- Group 1: Futibatinib (Cohort B)
- Group 2: Futibatinib (Cohort A)
- Group 3: Futibatinib (Cohort C)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the number of people receiving treatment in this experiment?
"Recruitment for this trial has been concluded. It was posted on August 24th 2020 and last updated on October 20th 2022. Those searching for alternative studies may find that there are presently 2387 trials enrolling those with gastroesophageal reflux disease, as well as 8 selection processes involving Futibatinib."
Is this a pioneering endeavor in its field?
"Presently, 8 ongoing clinical studies for Futibatinib span 24 different nations and 105 cities. This drug's initial trial was conducted in 2019 by Taiho Oncology Inc., with 168 participants completing the Phase 2 testing phase. Since then, zero subsequent studies have been executed."
What other experiments have researchers conducted with Futibatinib?
"At present, there are 8 ongoing studies exploring the application of Futibatinib with 2 trials reaching Phase 3. While most of these clinical tests are centered in Porto, Tennessee, over 250 other sites across the world have opened their doors to trial participants."
What potential hazards have been identified with the use of Futibatinib?
"Our team at Power allocated a rating of 2 to futibatinib's safety, as the medication has only been through Phase II trials and there is no clinical data that proves its efficacy."
What aims is this experiment endeavoring to achieve?
"Per the trial sponsor, Taiho Oncology Inc., this clinical study seeks to measure its primary outcomes -Overall Clinical Benefit Rate (CBR) in Cohort C- over a 6 month timeframe. Additionally, it will gauge secondary objectives such as Overall Survival (OS) across Cohorts A, B and C, Relapse Free Survival (RFS) among Cohort C patients, and Disease Control Rates (DCRs) amongst participants of both Cohort A & B."
How many medical facilities are conducting this experimental research?
"Currently, 15 locations are administering this clinical trial. These sites span from Washington to Dallas and Auburn in addition to many other cities. It is recommended that participants select the closest site for their convenience and reduce travel obligations."
Are there any enrollees being sought for this experiment at the moment?
"Currently, this clinical trial is not enrolling candidates. Initially posted on the 24th of August 2020 and last updated on October 20th 2022, participants are encouraged to look into other studies related to gastroesophageal reflux disease as there are currently 2387 trials recruiting patients. Additionally, 8 trials for Futibatinib have open enrollment too."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger